Treating skin afflictions/conditions with 2-amino-4-alkylaminopyrimidine 3-oxide compounds

ABSTRACT

Skin-soothing, -calmant and/or anti-inflammatory amounts of at least one 2-amino-4-alkylaminopyrimidine 3-oxide are well suited for therapeutically treating such afflictions/conditions of human skin as sensitive skin, skin discomfort, tautness, itchiness or swelling of the skin, blotchy red skin, or sensations of warming or burning of the skin.

CROSS-REFERENCE TO PRIORITY APPLICATION

[0001] This application claims priority under 35 U.S.C. §119 ofFR-98/14211, filed Nov. 12, 1998, hereby expressly incorporated byreference.

BACKGROUND OF THE INVENTION

[0002] 1. Technical Field of the Invention

[0003] The present invention relates to treating, for example soothingor calming, a variety of skin afflictions/conditions by administering toa candidate individual in need of such treatment an effective amount ofat least one 2-amino-4-alkylaminopyrimidine 3-oxide compound.

[0004] 2. Description of the Prior Art

[0005] It is known to this art that humans are subject to adversecutaneous challenges or stimuli which are characterized by a sensationof skin discomfort, tautness, itchiness, a sensation of burning orwarmth on the skin, or red blotches.

[0006] Active agents for controlling these types ofconditions/afflictions have long been sought by researchers in this art.

[0007] Although various active agents have already been proposed, aconstant interest remains to develop alternatives providing improvedskin-soothing/calmant or anti-inflammatory activity, in particular fortreating minor skin afflictions/conditions, such as, for example,sensitive skin, skin discomfort, tautness of the skin, itchiness of theskin, swelling of the skin, red blotchy skin or a sensation of burningor warmth on the skin.

SUMMARY OF THE INVENTION

[0008] Accordingly, a major object of the present invention is theprovision of improved regime/regimen for treating and alleviating thesymptoms of a variety of objectionable skin afflictions/conditions,while at the same time avoiding any appreciable side effects.

[0009] Briefly, the present invention features treating the aforesaidskin conditions/afflictions with a skin-soothing, -calmant oranti-inflammatory effective amount of at least one2-amino-4-alkylaminopyrimidine 3-oxide compound formulated into aphysiologically acceptable medium therefor.

DETAILED DESCRIPTION OF BEST MODE AND SPECIFIC/PREFERRED EMBODIMENTS OFTHE INVENTION

[0010] More particularly according to the present invention, by theexpression “physiologically acceptable medium” is intended a medium(e.g., vehicle, diluent or carrier) which is compatible with the skin,the mucous membranes, the nails and the hair of a human subject(hereinafter, simply the skin and/or the scalp).

[0011] The compounds of the 2-amino-4-alkylaminopyrimidine 3-oxidefamily which are well suited for administration according to theinvention have the general formula (I):

[0012] in which R₁ is an alkyl radical having from 1 to 20 carbon atoms,and Z is a hydrogen atom or a radical —OR₂, wherein R₂ is an alkylradical having from 1 to 12 carbon atoms, as well as the acylderivatives and acid addition salts thereof.

[0013] According to the invention, by the expression “alkyl radical” isintended a linear or branched acyclic radical originating via theremoval of a hydrogen atom from the molecule of a hydrocarbon, such as,for example, a methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl,octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl,hexadecyl, heptadecyl, octadecyl, nonadecyl or eicosadecyl radical.

[0014] In one preferred embodiment of the invention, R₁ is an alkylradical having from 6 to 12 carbon atoms, such as, for example, a hexyl,heptyl, octyl, nonyl, decyl, undecyl or dodecyl radical.

[0015] In another preferred embodiment of the invention, R₂ is an alkylradical having from 2 to 6 carbon atoms, such as, for example, an ethyl,propyl, butyl, pentyl or hexyl radical.

[0016] Preferred compounds according to the invention include:

[0017] 2-amino-4-methylaminopyrimidine 3-oxide;

[0018] 2-amino-4-ethylaminopyrimidine 3-oxide;

[0019] 2-amino-4-propylaminopyrimidine 3-oxide;

[0020] 2-amino-4-butylaminopyrimidine 3-oxide;

[0021] 2-amino-4-pentylaminopyrimidine 3-oxide;

[0022] 2-amino-4-hexylaminopyrimidine 3-oxide;

[0023] 2-amino-4-heptylaminopyrimidine 3-oxide;

[0024] 2-amino-4-octylaminopyrimidine 3-oxide;

[0025] 2-amino-4-nonylaminopyrimidine 3-oxide;

[0026] 2-amino-4-decylaminopyrimidine 3-oxide;

[0027] 2-amino-4-undecylaminopyrimidine 3-oxide;

[0028] 2-amino-4-dodecylaminopyrimidine 3-oxide;

[0029] 2-amino-4-tridecylaminopyrimidine 3-oxide;

[0030] 2-amino-4-tetradecylaminopyrimidine 3-oxide;

[0031] 2-amino-4-pentadecylaminopyrimidine 3-oxide;

[0032] 2-amino-4-hexadecylaminopyrimidine 3-oxide;

[0033] 2-amino-4-heptadecylaminopyrimidine 3-oxide;

[0034] 2-amino-4-octadecylaminopyrimidine 3-oxide;

[0035] 2-amino-4-nonadecylaminopyrimidine 3-oxide;

[0036] 2-amino-4-eicosadecylaminopyrimidine 3-oxide;

[0037] 2-amino-4-methylamino-6-methoxypyrimidine 3-oxide;

[0038] 2-amino-4-ethylamino-6-methoxypyrimidine 3-oxide;

[0039] 2-amino-4-propylamino-6-methoxypyrimidine 3-oxide;

[0040] 2-amino-4-butylamino-6-methoxypyrimidine 3-oxide;

[0041] 2-amino-4-pentylamino-6-methoxypyrimidine 3-oxide;

[0042] 2-amino-4-hexylamino-6-methoxypyrimidine 3-oxide;

[0043] 2-amino-4-heptylamino-6-methoxypyrimidine 3-oxide;

[0044] 2-amino-4-octylamino-6-methoxypyrimidine 3-oxide;

[0045] 2-amino-4-nonylamino-6-methoxypyrimidine 3-oxide;

[0046] 2-amino-4-decylamino-6-methoxypyrimidine 3-oxide;

[0047] 2-amino-4-undecylamino-6-methoxypyrimidine 3-oxide;

[0048] 2-amino-4-dodecylamino-6-methoxypyrimidine 3-oxide;

[0049] 2-amino-4-tridecylamino-6-methoxypyrimidine 3-oxide;

[0050] 2-amino-4-tetradecylamino-6-methoxypyrimidine 3-oxide;

[0051] 2-amino-4-pentadecylamino-6-methoxypyrimidine 3-oxide;

[0052] 2-amino-4-hexadecylamino-6-methoxypyrimidine 3-oxide;

[0053] 2-amino-4-heptadecylamino-6-methoxypyrimidine 3-oxide;

[0054] 2-amino-4-octadecylamino-6-methoxypyrimidine 3-oxide;

[0055] 2-amino-4-nonadecylamino-6-methoxypyrimidine 3-oxide;

[0056] 2-amino-4-eicosadecylamino-6-methoxypyrimidine 3-oxide;

[0057] 2-amino-4-methylamino-6-ethoxypyrimidine 3-oxide;

[0058] 2-amino-4-ethylamino-6-ethoxypyrimidine 3-oxide;

[0059] 2-amino-4-propylamino-6-ethoxypyrimidine 3-oxide;

[0060] 2-amino-4-butylamino-6-ethoxypyrimidine 3-oxide;

[0061] 2-amino-4-pentylamino-6-ethoxypyrimidine 3-oxide;

[0062] 2-amino-4-hexylamino-6-ethoxypyrimidine 3-oxide;

[0063] 2-amino-4-heptylamino-6-ethoxypyrimidine 3-oxide;

[0064] 2-amino-4-octylamino-6-ethoxypyrimidine 3-oxide;

[0065] 2-amino-4-nonylamino-6-ethoxypyrimidine 3-oxide;

[0066] 2-amino-4-decylamino-6-ethoxypyrimidine 3-oxide;

[0067] 2-amino-4-undecylamino-6-ethoxypyrimidine 3-oxide;

[0068] 2-amino-4-dodecylamino-6-ethoxypyrimidine 3-oxide;

[0069] 2-amino-4-tridecylamino-6-ethoxypyrimidine 3-oxide;

[0070] 2-amino-4-tetradecylamino-6-ethoxypyrimidine 3-oxide;

[0071] 2-amino-4-pentadecylamino-6-ethoxypyrimidine 3-oxide;

[0072] 2-amino-4-hexadecylamino-6-ethoxypyrimidine 3-oxide;

[0073] 2-amino-4-heptadecylamino-6-ethoxypyrimidine 3-oxide;

[0074] 2-amino-4-octadecylamino-6-ethoxypyrimidine 3-oxide;

[0075] 2-amino-4-nonadecylamino-6-ethoxypyrimidine 3-oxide;

[0076] 2-amino-4-eicosadecylamino-6-ethoxypyrimidine 3-oxide;

[0077] 2-amino-4-methylamino-6-propyloxypyrimidine 3-oxide;

[0078] 2-amino-4-ethylamino-6-propyloxypyrimidine 3-oxide;

[0079] 2-amino-4-propylamino-6-propyloxypyrimidine 3-oxide;

[0080] 2-amino-4-butylamino-6-propyloxypyrimidine 3-oxide;

[0081] 2-amino-4-pentylamino-6-propyloxypyrimidine 3-oxide;

[0082] 2-amino-4-hexylamino-6-propyloxypyrimidine 3-oxide;

[0083] 2-amino-4-heptylamino-6-propyloxypyrimidine 3-oxide;

[0084] 2-amino-4-octylamino-6-propyloxypyrimidine 3-oxide;

[0085] 2-amino-4-nonylamino-6-propyloxypyrimidine 3-oxide;

[0086] 2-amino-4-decylamino-6-propyloxypyrimidine 3-oxide;

[0087] 2-amino-4-undecylamino-6-propyloxypyrimidine 3-oxide;

[0088] 2-amino-4-dodecylamino-6-propyloxypyrimidine 3-oxide;

[0089] 2-amino-4-tridecylamino-6-propyloxypyrimidine 3-oxide;

[0090] 2-amino-4-tetradecylamino-6-propyloxypyrimidine 3-oxide;

[0091] 2-amino-4-pentadecylamino-6-propyloxypyrimidine 3-oxide;

[0092] 2-amino-4-hexadecylamino-6-propyloxypyrimidine 3-oxide;

[0093] 2-amino-4-heptadecylamino-6-propyloxypyrimidine 3-oxide;

[0094] 2-amino-4-octadecylamino-6-propyloxypyrimidine 3-oxide;

[0095] 2-amino-4-nonadecylamino-6-propyloxypyrimidine 3-oxide;

[0096] 2-amino-4-eicosadecylamino-6-propyloxypyrimidine 3-oxide;

[0097] 2-amino-4-methylamino-6-butyloxypyrimidine 3-oxide;

[0098] 2-amino-4-ethylamino-6-butyloxypyrimidine 3-oxide;

[0099] 2-amino-4-propylamino-6-butyloxypyrimidine 3-oxide;

[0100] 2-amino-4-butylamino-6-butyloxypyrimidine 3-oxide;

[0101] 2-amino-4-pentylamino-6-butyloxypyrimidine 3-oxide;

[0102] 2-amino-4-hexylamino-6-butyloxypyrimidine 3-oxide;

[0103] 2-amino-4-heptylamino-6-butyloxypyrimidine 3-oxide;

[0104] 2-amino-4-octylamino-6-butyloxypyrimidine 3-oxide;

[0105] 2-amino-4-nonylamino-6-butyloxypyrimidine 3-oxide;

[0106] 2-amino-4-decylamino-6-butyloxypyrimidine 3-oxide;

[0107] 2-amino-4-undecylamino-6-butyloxypyrimidine 3-oxide;

[0108] 2-amino-4-dodecylamino-6-butyloxypyrimidine 3-oxide;

[0109] 2-amino-4-tridecylamino-6-butyloxypyrimidine 3-oxide;

[0110] 2-amino-4-tetradecylamino-6-butyloxypyrimidine 3-oxide;

[0111] 2-amino-4-pentadecylamino-6-butyloxypyrimidine 3-oxide;

[0112] 2-amino-4-hexadecylamino-6-butyloxypyrimidine 3-oxide;

[0113] 2-amino-4-heptadecylamino-6-butyloxypyrimidine 3-oxide;

[0114] 2-amino-4-octadecylamino-6-butyloxypyrimidine 3-oxide;

[0115] 2-amino-4-nonadecylamino-6-butyloxypyrimidine 3-oxide;

[0116] 2-amino-4-eicosadecylamino-6-butyloxypyrimidine 3-oxide; and thebranched isomers thereof.

[0117] More preferred compounds according to the invention include:

[0118] 2-amino-4-hexylaminopyrimidine 3-oxide;

[0119] 2-amino-4-octylaminopyrimidine 3-oxide;

[0120] 2-amino-4-dodecylaminopyrimidine 3-oxide;

[0121] 2-amino-4-octylamino-6-butyloxypyrimidine 3-oxide.

[0122] Even more preferred are 2-amino-4-dodecylaminopyrimidine 3-oxide,and 2-amino-4-octylamino-6-butyloxypyrimidine 3-oxide.

[0123] It will of course be appreciated that the subject2-amino-4-alkylaminopyrimidine 3-oxide compounds can be administeredeither alone or in admixture.

[0124] In another embodiment of the invention compositions areformulated, in a physiologically acceptable medium therefor, comprisingan effective amount of at least one 2-amino-4-alkylaminopyrimidine3-oxide compound having the general formula (I), such compound orcomposition being well suited for controlling or alleviating thesymptons of sensitive skin, skin disruptions, such as skin discomfort,tautness of the skin, itchiness of the skin, swelling of the skin,blotchy red skin or a sensation of burning or warming of the skin.

[0125] The compositions of the invention comprising at least one2-amino-4-alkylaminopyrimidine 3-oxide compound are well suited forcosmetic applications.

[0126] The amount of the 2-amino-4-alkylaminopyrimidine 3-oxide compoundrequired according to the invention of course depends on the desiredeffect and should be an amount which is effective for controlling theobjectionable skin disruptions sought to be treated.

[0127] By way of example, the amount of compounds of the2-amino-4-alkylaminopyrimidine 3-oxide family which are advantageouslyadministered according to the invention typically ranges, for example,from 0.01% to 20% and preferably from 0.05% to 10% of the total weightof the composition.

[0128] The subject compositions are conveniently administered via anyroute, preferably via topical application onto the skin.

[0129] The physiologically acceptable medium (vehicle, diluent orcarrier)into which the 2-amino-4-alkylaminopyrimidine 3-oxide compoundis formulated according to the invention may be anhydrous or aqueous. Bythe expression “anhydrous medium” is intended a solvent mediumcontaining less than 1% water. This medium is advantageously a solventor mixture of solvents selected, in particular, from among C₂-C₄ loweralcohols, for example ethyl alcohol, alkylene glycols, for examplepropylene glycol, and alkylene glycol or dialkylene glycol alkyl ethers,in which the alkyl or alkylene radicals contain from 1 to 4 carbonatoms. By the expression “aqueous medium” is intended a mediumadvantageously of water or a mixture of water and anotherphysiologically acceptable solvent, selected in particular from amongthe organic solvents indicated above. In the latter event, these othersolvents, when they are indeed present, constitute about 5% to 95% byweight of the composition.

[0130] It is possible for the physiologically acceptable medium tocontain other additives and adjuvants commonly formulated intocosmetics, such as surfactants, thickeners or gelling agents, cosmeticagents, preservatives or acidifying or basifying agents that are per sewell known to this art, and in amounts which are sufficient to providethe desired physical state, in particular the form of a more or lessthickened lotion, a gel, an emulsion or a cream. These can optionally beprovided in a form pressurized as an aerosol or vaporized from apump-dispenser bottle.

[0131] According to the invention, the subject compositions can compriseat least one compound of formula (I) with other active agents. Exemplarysuch other active agents include:

[0132] (a) other skin-soothing agents or calmants, for instance peptidessuch as, for example, the tripeptide lysine-proline-valine;

[0133] (b) keratolytic agents such as α- and β-hydroxycarboxylic acidsor β-ketocarboxylic acids, their salts, amides or esters and, moreparticularly, hydroxy acids such as glycolic acid, lactic acid,salicylic acid, citric acid and fruit acids in general, and5-n-octanoylsalicylic acid;

[0134] (c) free-radical scavengers, such as α-tocopherol or estersthereof, superoxide dismutases, certain metal-chelating agents orascorbic acid and esters thereof;

[0135] (d) extracts of plant, marine or bacterial origin.

[0136] Other compounds can also be thus formulated, namely, for example,phospholipids such as lecithin, linoleic acid, linolenic acid, salicylicacid and the derivatives thereof described in FR-2,581,542, such assalicylic acid derivatives bearing an alkanoyl group substituent havingfrom 2 to 12 carbon atoms in position 5 of the benzene ring,hydroxycarboxylic or ketocarboxylic acids and esters thereof,carotenoids, eicosatetraenoic acid and eicosatrienoic acid or the estersand amides thereof, and vitamin D and derivatives thereof.

[0137] The 2-amino-4-alkylaminopyrimidine 3-oxide compound, or cosmeticcomposition comprised thereof, is most conveniently topically appliedonto those areas of the skin and/or the scalp of an individual requiringsuch treatment, optionally maintained in contact therewith for severalhours and optionally rinsed therefrom.

[0138] Thus, the present invention also features a skin-soothing orcalmant cosmetic regime/regimen for treating sensitive skin, skindisruptions such as skin discomfort, tautness of the skin, itchiness ofthe skin, swelling of the skin, blotchy red skin or a burning sensationor sensation of warmth on the skin, entailing topically applying acosmetic composition comprising at least one2-amino-4-alkylaminopyrimidine 3-oxide compound onto the skin and/or thescalp of an individual in need of such treatment, maintaining suchcomposition in contact with the skin and/or the scalp for such period oftime as required to elicit the desired therapeutic/anti-inflammatoryeffect, and optionally rinsing the composition therefrom.

[0139] Such cosmetic treatment permits enhancing the aesthetics andcomfort of the skin and/or the scalp and enhancing an individual'scomfort by treating/alleviating the effects of adverse challenges on theskin.

[0140] In order to further illustrate the present invention and theadvantages thereof, the following specific examples are given, it beingunderstood that same are intended only as illustrative and in nowiselimitative.

EXAMPLES

[0141] The following are specific examples of compositions according tothe present invention; each was formulated by simply intimately admixingthe various constituents thereof.

[0142] Lotion Lotion: 2-Amino-4-dodecylaminopyrimidine 3-oxide 1.500%Propylene glycol 10.000% Isopropyl alcohol qs 100%

[0143] 1 ml of this lotion is applied to the scalp at a rate of once ortwice a day. Gel: Chimexane NS¹ 1.800% Monosodium stearoylglutamate0.200% 2-Amino-4-octylamino-6-butyloxypyrimidine 2.000% 3-oxide Carbomer0.200% Triethanolamine qs pH = 7 Preservatives qs Fragrances qsDemineralized water qs 100%

[0144] This gel is applied to the skin once or twice a day. Lotion:2-Amino-4-dodecylaminopyrimidine 3-oxide 1.000% Propylene glycol 30.000%Ethyl alcohol 40.500% Water qs 100%

[0145] This lotion is applied once or twice a day, at a rate of 1 ml perapplication. Thickened lotion: 2-Amino-4-octylaminopyrimidine 3-oxide2.000% Kawaine 2.000% Hydroxypropylcellulose marketed by 3.500% Herculesunder the trademark Klucel G¹ Ethyl alcohol qs 100%

[0146] This thickened lotion is applied once or twice a day. Lotion:Chimexane NL¹ 0.475% Cholesterol 0.475% Monosodium stearoylglutamate0.050% 2-Amino-4-dodecylaminopyrimidine 0.500% 3-oxide Preservatiges qsDyes qs Fragrances qs Demineralized water qs 100%

[0147] This lotion is applied once or twice a day, at a rate of 1 ml perapplication. Lotion: 2-Amino-4-hexylaminopyrimidine 3-oxide 0.100%Propylene glycol monomethyl ether marketed 20.000% under the trademarkDowanol PM¹ by Dow Chemical Hydroxypropylcellulose marketed by 3.000%Hercules under the trademark Klucel G¹ Ethyl alcohol 40.000% Water qs100%

[0148] This thickened lotion is applied at a rate of 1 ml perapplication. Day cream: 2-Amino-4-dodecylaminopyrimidine 3-oxide 1.000%Sucrose stearate 4.000% Stearyl alcohol 2.000% Cyclohexasiloxane 9.000%Mineral oil 4.000% Glycerol 5.000% Xanthan gum 0.300% Carbomer 0.500%Preservatives 0.300% Fragrances 0.300% Water qs 100% Care fluid:2-Amino-4-dodecylaminopyrimidine 3-oxide 1.000% Stearyl alcohol 0.400%Sorbitan stearate 1.500% Glycerol 5.000% Xanthan gum 0.200% Carbomer0.100% Cyclohexasiloxane 7.000% Preservatives 0.300% Fragrances 0.200%Water qs 100% Lotion: 2-Amino-4-dodecylaminopyrimidine 3-oxide 0.500%Propylene glycol 2.000% Extract of cornflower 0.100% Preservatives0.100% PEG 60 hydrogenated castor oil 0.400% Fragrances 0.100% Water qs100%

[0149] While the invention has been described in terms of variouspreferred embodiments, the skilled artisan will appreciate that variousmodifications, substitutions, omissions, and changes may be made withoutdeparting from the spirit thereof. Accordingly, it is intended that thescope of the present invention be limited solely by the scope of thefollowing claims, including equivalents thereof.

What is claimed is:
 1. A regime/regimen for treatingafflictions/conditions of human skin and/or scalp, comprisingadministering to a candidate individual in need of such treatment, forsuch period of time as required to elicit a skin-soothing, -calmantand/or anti-inflammatory response, a thus effective amount of at leastone 2-amino-4-alkylaminopyrimidine 3-oxide compound.
 2. Theregime/regimen as defined by claim 1 , comprising topically applyingsaid effective amount of at least one 2-amino-4-alkylaminopyrimidine3-oxide compound onto the skin and/or scalp of such candidate individualin need of such treatment.
 3. The regime/regimen as defined by claim 2 ,said effective amount of at least one 2-amino-4-alkylaminopyrimidine3-oxide compound being formulated into physiologically acceptablevehicle, diluent or carrier therefor.
 4. A regime/regimen for treatingsensitive skin, skin discomfort, tautness, itchiness or swelling of theskin, blotchy red skin, or sensations of burning or warming of the skin,comprising administering to a candidate individual in need of suchtreatment, for such period of time as required to elicit askin-soothing, -calmant or anti-inflammatory response, a thus effectiveamount of at least one 2-amino-4-alkylaminopyrimidine 3-oxide compound.5. The regime/regimen as defined by claim 1 , said at least one2-amino-4-alkylaminopyrimidine 3-oxide compound having the structuralformula (I):

in which R₁ is an alkyl radical having from 1 to 20 carbon atoms, and Zis a hydrogen atom or a radical —OR₂, wherein R₂ is an alkyl radicalhaving from 1 to 12 carbon atoms, or an acyl derivative or acid additionsalt thereof.
 6. The regime/regimen as defined by claim 5 , whereinformula (I), R₁ is an alkyl radical having from 6 to 12 carbon atoms. 7.The regime/regimen as defined by claim 5 , wherein formula (I), R₂ is analkyl radical having from 1 to 12 carbon atoms.
 8. The regime/regimen asdefined by claim 5 , said at least one 2-amino-4-alkylaminopyrimidine3-oxide compound having the structural formula (I) being selected fromamong 2-amino-4-methylaminopyrimidine 3-oxide;2-amino-4-ethylaminopyrimidine 3-oxide; 2-amino-4-propylaminopyrimidine3-oxide; 2-amino-4-butylaminopyrimidine 3-oxide;2-amino-4-pentylaminopyrimidine 3-oxide; 2-amino-4-hexylaminopyrimidine3-oxide; 2-amino-4-heptylaminopyrimidine 3-oxide;2-amino-4-octylaminopyrimidine 3-oxide; 2-amino-4-nonylaminopyrimidine3-oxide; 2-amino-4-decylaminopyrimidine 3-oxide;2-amino-4-undecylaminopyrimidine 3-oxide;2-amino-4-dodecylaminopyrimidine 3-oxide;2-amino-4-tridecylaminopyrimidine 3-oxide;2-amino-4-tetradecylaminopyrimidine 3-oxide;2-amino-4-pentadecylaminopyrimidine 3-oxide;2-amino-4-hexadecylaminopyrimidine 3-oxide;2-amino-4-heptadecylaminopyrimidine 3-oxide;2-amino-4-octadecylaminopyrimidine 3-oxide;2-amino-4-nonadecylaminopyrimidine 3-oxide;2-amino-4-eicosadecylaminopyrimidine 3-oxide;2-amino-4-methylamino-6-methoxypyrimidine 3-oxide;2-amino-4-ethylamino-6-methoxypyrimidine 3-oxide;2-amino-4-propylamino-6-methoxypyrimidine 3-oxide;2-amino-4-butylamino-6-methoxypyrimidine 3-oxide;2-amino-4-pentylamino-6-methoxypyrimidine 3-oxide;2-amino-4-hexylamino-6-methoxypyrimidine 3-oxide;2-amino-4-heptylamino-6-methoxypyrimidine 3-oxide; 2-amino-4-octylamino-6-methoxypyrimidine 3-oxide;2-amino-4-nonylamino-6-methoxypyrimidine 3-oxide;2-amino-4-decylamino-6-methoxypyrimidine 3-oxide;2-amino-4-undecylamino-6-methoxypyrimidine 3-oxide;2-amino-4-dodecylamino-6-methoxypyrimidine 3-oxide;2-amino-4-tridecylamino-6-methoxypyrimidine 3-oxide;2-amino-4-tetradecylamino-6-methoxypyrimidine 3-oxide;2-amino-4-pentadecylamino-6-methoxypyrimidine 3-oxide;2-amino-4-hexadecylamino-6-methoxypyrimidine 3-oxide;2-amino-4-heptadecylamino-6-methoxypyrimidine 3-oxide;2-amino-4-octadecylamino-6-methoxypyrimidine 3-oxide;2-amino-4-nonadecylamino-6-methoxypyrimidine 3-oxide;2-amino-4-eicosadecylamino-6-methoxypyrimidine 3-oxide;2-amino-4-methylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-ethylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-propylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-butylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-pentylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-hexylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-heptylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-octylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-nonylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-decylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-undecylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-dodecylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-tridecylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-tetradecylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-pentadecylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-hexadecylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-heptadecylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-octadecylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-nonadecylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-eicosadecylamino-6-ethoxypyrimidine 3-oxide;2-amino-4-methylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-ethylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-propylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-butylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-pentylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-hexylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-heptylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-octylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-nonylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-decylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-undecylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-dodecylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-tridecylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-tetradecylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-pentadecylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-hexadecylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-heptadecylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-octadecylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-nonadecylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-eicosadecylamino-6-propyloxypyrimidine 3-oxide;2-amino-4-methylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-ethylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-propylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-butylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-pentylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-hexylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-heptylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-octylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-nonylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-decylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-undecylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-dodecylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-tridecylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-tetradecylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-pentadecylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-hexadecylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-heptadecylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-octadecylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-nonadecylamino-6-butyloxypyrimidine 3-oxide;2-amino-4-eicosadecylamino-6-butyloxypyrimidine 3-oxide; and thebranched isomers thereof.
 9. The regime/regimen as defined by claim 8 ,said at least one 2-amino-4-alkylaminopyrimidine 3-oxide compoung havingthe structural formula (I) being selected from among2-amino-4-hexylaminopyrimidine 3-oxide; 2-amino-4-octylaminopyrimidine3-oxide; 2-amino-4-dodecylaminopyrimidine 3-oxide;2-amino-4-octylamino-6-butyloxypyrimidine 3-oxide.
 10. Theregime/regimen as defined by claim 9 , said at least one2-amino-4-alkylaminopyrimidine 3-oxide compound having the structuralformula (I) being selected from between 2-amino-4-dodecylaminopyrimidine3-oxide and 2-amino-4-octylamino-6-butyloxypyrimidine 3-oxide.
 11. Theregime/regimen as defined by claim 2 , comprising maintaining saideffective amount of said at least one 2-amino-4-alkylaminopyrimidine3-oxide compound on the skin and/or scalp of the candidate individual inneed of such treatment, for such period of time as required to elicitthe desired therapeutic effect, and optionally rinsing same therefrom.12. A cosmetic/dermatological composition suited for soothing or calminga variety of afflictions/conditions of human skin and/or scalp,comprising an effective amount of at least one2-amino-4-alkylaminopyrimidine 3-oxide compound, formulated into atopically applicable, physiologically acceptable vehicle, diluent orcarrier therefor.
 13. The cosmetic/dermatological composition as definedby claim 12 , comprising from 0.01% to 20% by weight of said at leastone 2-amino-4-alkylaminopyrimidine 3-oxide compound.
 14. Thecosmetic/dermatological composition as defined by claim 12 , comprisingfrom 0.05% to 10% by weight of said at least one2-amino-4-alkylaminopyrimidine 3-oxide compound.
 15. Thecosmetic/dermatological composition as defined by claim 12 , formulatedas a thickened lotion, gel, emulsion, cream, aerosol, or vapor.
 16. Thecosmetic/dermatological composition as defined by claim 12 , furthercomprising an effective amount of at least one surfactant, thickener,gelling agent, cosmetic agent, preservative, acidifying or basifyingagent.
 17. The cosmetic/dermatological composition as defined by claim12 , further comprising an effective amount of at least oneskin-soothing/calmant agent other than a 2-amino-4-alkylaminopyrimidine3-oxide, keratolytic agent, free-radical scavenger, plant, marine orbacterial extract, phospholipid, linoleic acid, linolenic acid,salicylic acid or derivative thereof, hydroxycarboxylic orketocarboxylic acid or ester thereof, carotenoid, eicosatetraenoic acidor eicosatrienoic acid or ester or amide thereof, vitamin D orderivative thereof.